Faculty Perspectives: PI3K Inhibitors: Efficacy in Hematologic Malignancies and Management of Treatment-Related Adverse Events - TON

Faculty Perspectives: PI3K Inhibitors: Efficacy in Hematologic Malignancies and Management of Treatment-Related Adverse Events

TLG1589

Lymphomas are a heterogeneous group of malignancies that are associated with substantial morbidity and mortality. Although standard chemoimmunotherapy regimens lead to durable remissions in a substantial proportion of patients, many individuals will relapse and develop refractory disease. Therefore, a clear need exists for the development of novel therapies that are designed to treat relapsed/refractory B-cell malignancies. Read More ›

The development and utilization of novel therapies, including small-molecule agents, have undoubtedly altered the treatment landscape for many indolent non-Hodgkin B-cell malignancies in the frontline and relapsed/ refractory settings. The availability of such agents as Bruton tyrosine kinase, BCL2, and phosphoinositide 3-kinase (PI3K) inhibitors addresses an unmet need among oncologists and advanced practice providers (APPs) who are seeking additional therapeutic options for their patients, particularly those with relapsed/refractory disease. Read More ›


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: